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Abstract
Background: Indacaterol is a once-daily long-acting inhaled b2-agonist indicated for maintenance treatment of
moderate-to-severe chronic obstructive pulmonary disease (COPD). The large inter-patient and inter-study variability
in forced expiratory volume in 1 second (FEV1) with bronchodilators makes determination of optimal doses difficult
in conventional dose-ranging studies. We considered alternative methods of analysis.
Methods: We utilized a novel modelling approach to provide a robust analysis of the bronchodilatory dose response
to indacaterol. This involved pooled analysis of study-level data to characterize the bronchodilatory dose response,
and nonlinear mixed-effects analysis of patient-level data to characterize the impact of baseline covariates.
Results: The study-level analysis pooled summary statistics for each steady-state visit in 11 placebo-controlled studies.
These study-level summaries encompassed data from 7476 patients at indacaterol doses of 18.75-600 μg once daily, and
showed that doses of 75 μg and above achieved clinically important improvements in predicted trough FEV1 response.
Indacaterol 75 μg achieved 74% of the maximum effect on trough FEV1, and exceeded the midpoint of the 100-140 mL
range that represents the minimal clinically important difference (MCID; ≥120 mL vs placebo), with a 90% probability
that the mean improvement vs placebo exceeded the MCID. Indacaterol 150 μg achieved 85% of the model-predicted
maximum effect on trough FEV1 and was numerically superior to all comparators (99.9% probability of exceeding MCID).
Indacaterol 300 μg was the lowest dose that achieved the model-predicted maximum trough response.
The patient-level analysis included data from 1835 patients from two dose-ranging studies of indacaterol 18.75-600 μg
once daily. This analysis provided a characterization of dose response consistent with the study-level analysis, and
demonstrated that disease severity, as captured by baseline FEV1, significantly affects the dose response, indicating that
patients with more severe COPD require higher doses to achieve optimal bronchodilation.
Conclusions: Comprehensive assessment of the bronchodilatory dose response of indacaterol in COPD patients
provided a robust confirmation that 75 μg is the minimum effective dose, and that 150 and 300 μg are expected
to provide optimal bronchodilation, particularly in patients with severe disease.
Introduction
Indacaterol is the first long-acting inhaled b2-agonist
indicated for once-daily maintenance treatment in
patients with moderate-to-severe chronic obstructive
pulmonary disease (COPD), and has been approved in
more than 40 countries (including throughout the
European Union) for use at doses of 150 and 300 μg
once daily. The efficacy and safety of indacaterol was
evaluated in an extensive Phase III clinical programme
in which patients received doses of up to 600 μgo n c e
daily for up to 52 weeks [1-4]. In an analysis of data
from 801 patients with moderate-to-severe COPD after
2w e e k so ft r e a t m e n t( S t a g e1o faP h a s eI I / I I Is t u d y
employing an adaptive seamless design), indacaterol
150 μg once daily was identified as the lowest dose that
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any medium, provided the original work is properly cited.was numerically superior to the active comparators (for-
moterol twice daily and open label tiotropium once
daily) and, along with the next highest dose (300 μg),
was selected for further evaluation [5]. This additional
evaluation (Stage 2 of the adaptive seamless design
study) showed that indacaterol 150 and 300 μg provided
statistically significant and clinically relevant improve-
ments in trough forced expiratory volume in 1 second
(FEV1) vs placebo up to 26 weeks [2]. Although indaca-
terol 150 and 300 μg had similar effects on trough
FEV1, the higher dose was associated with incremental
benefits in terms of symptomatic relief, such as dys-
pnoea [2], particularly for patients with more severe
COPD. Further, the overall clinical trial programme has
indicated that indacaterol had a similar safety and toler-
ability profile across all of the doses evaluated [1-4,6].
Conventional dose-ranging trials rely on hypothesis
testing and use placebo corrected mean responses to
c o m p a r ed o s el e v e l sa n dd e t e r m i n et h ee x i s t e n c eo fa
dose response. If at least one dose achieves a statistically
significant difference compared with placebo for an
appropriate endpoint (e.g. trough FEV1 for evaluation of
bronchodilators in COPD), a dose response is estab-
lished and a target dose can be selected as the smallest
dose that differs from placebo and has both a clinically
relevant effect and an acceptable safety profile [7].
Several such studies have evaluated dose responses for
bronchodilators in patients with COPD [8-12]. In Phase
II dose-ranging studies in COPD, indacaterol consis-
tently demonstrated bronchodilator efficacy that was
superior to placebo, regardless of the dose tested [13,14].
The potential of indacaterol as a bronchodilator is best
appreciated when the responses across all the tested dose
levels are expressed together in a dose-response relation-
ship. However, given the inherent variability in measure-
ments of lung function relative to the drug-induced
change achieved by bronchodilators, accurate characteri-
zation of the dose response relationship is difficult.
Figure 1 shows individual-patient trough FEV1 data over
a range of indacaterol doses (using data from the studies
included in the patient-level analysis discussed below)
and includes a locally weighted scatterplot smoothing
(LOESS) curve to highlight the main trend. While the
overall FEV1 in the population varied from about 0.5 to
3 L, the maximum drug response vs placebo is under
200 mL as depicted in the figure inset. This is indicative
of the low signal-to-noise ratio of the bronchodilatory
response in COPD. The impact of this issue on the inter-
pretation of study results is best illustrated by consider-
ing the variability of a single dose level within and
between trials. Figure 2 depicts the variability in trough
FEV1 response to indacaterol 150 μg across six different
studies. Each panel represents the results from one trial.
The data points are the least square means (LSM) for
each study visit. The grey area within each panel provides
a visual representation of the range of responses observed
within each trial. The panels are ranked by the median
response observed in each trial. This figure shows that
the intra- and inter-study variability in mean trough
FEV1 may be as high as 50 mL, whereas the inter-study
variability in median response may be about 60 mL. The
implications of this observation is that relying on single
LSM values does not provide adequate precision to easily
differentiate between dose levels.
To overcome this inherent difficulty in using conven-
tional methodology to accurately establish dose responses
for bronchodilators in COPD, two alternative approaches
were explored. The first approach focused on the study
level results typically reported for bronchodilator assess-
ment. The aim of this approach was to use study level
LSM from COPD studies in the indacaterol development
programme to provide estimates of the dose response
and of the precision of typical study level data used for
the purpose of dose selection. The second approach
Figure 1 Individual-patient trough FEV1 data with LOESS curve,
with zoom-in on the LOESS curve in the range 1200-1500 mL.
Figure 2 Improvement in trough FEV1 (mL) with indacaterol
150 μg observed at different days in six of the studies in the
study-level analysis ranked by median value.
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aim of this approach was also to determine the dose
response while exploring individual patient characteris-
tics that may affect the drug response and hence dose
selection. To our knowledge, this is the first time that
these novel modelling methods have been used to char-
acterize dose response in COPD patients receiving a
bronchodilator.
Methods
Two approaches were used: 1) an integrated analysis of
study-level data, and 2) an integrated analysis of patient-
level data. The objectives of both analyses were to pro-
vide a precise quantitative characterization of the dose-
response relationship of indacaterol and the responses to
comparators used in some trials. The key metrics of
interest were: the minimume f f e c t i v ed o s e( M E D ) ,
defined as the lowest dose that achieved a median trough
FEV1 that exceeded the midpoint of the 100-140 mL
range considered to represent the minimum clinically
important difference (MCID) for FEV1 in COPD (i.e., a
difference from placebo of ≥120 mL) [15]; the optimal
dose, defined as the lowest dose that achieved or
exceeded the criteria for the MED and was superior to all
active comparators; and the maximum dose defined as
the lowest dose with a 95% confidence interval (CI) for
the predicted response that includes the expected maxi-
mum response. A further objective of the patient-level
analysis was to determine patient-level characteristics
that influenced the dose response, and so may influence
dose selection decisions.
Data sources
The study-level pooled analysis included data from 7476
patients enrolled in 11 placebo-controlled studies in
which indacaterol was administered to patients with
COPD at doses of 18.75 to 600 μg once daily (Table 1).
The analysis involved placebo-controlled studies that
included assessment of trough FEV1 and had a duration
of at least 14 days. Indacaterol was compared with for-
moterol in two studies, with salmeterol in four studies
and with tiotropium in one study. Note all comparator
data was at steady-state and assessed at the same study
visits in the respective studies. LSM contrasts to placebo
and associated standard errors were collected from indi-
vidual study reports to create the study-level pooled ana-
lysis dataset. The LSM estimates were obtained after
various covariate adjustments in the original statistical
analyses of each individual study (details of covariate
adjustments are included in Additional file 1).
To evaluate FEV1 at steady state, the analysis pooled
study results from Week 2 up to Month 6 of therapy. This
timescale was selected as indacaterol is known to have
reached both pharmacodynamic and pharmacokinetic
steady state by Week 2 [2]. For example, in a study of
1683 patients, improvements in mean trough FEV1 with
indacaterol 150 and 300 μg vs placebo were similar at
Weeks 2, 12 and 26, with no decline over this period [2].
The patient-level analysis evaluated trough FEV1 in
1835 patients enrolled in two dose-ranging studies in
which indacaterol was delivered using the single-dose
dry powder inhaler that is used for the commercially-
available product. As one of these studies had a duration
of 2 weeks and the other had key dose-ranging data over
the same duration [5], the patient-level analysis consid-
ered trough FEV1 measurements only after 2 weeks of
treatment.
Study-level analysis
The primary objective of the study-level analysis was
to characterize the dose-response relationship for
indacaterol in patients with COPD. The analysis of
steady state trough FEV1 was conducted using an Emax
model:
(Emax + δi + γij) × doseij
ED50 + doseij
(1)
where i is an index for study and j for study arm, Emax
is the (model-predicted) maximum possible response,
and ED50 characterizes drug potency and corresponds to
the indacaterol dose producing 50% of the maximum
effect. The model included between-study (δi)a n d
within-study, between-visit (gij) variability on Emax and
was analysed using a Bayesian methodology.
As the summary data used in this analysis are con-
trasts to placebo, the model was constrained to have a
null response with placebo (dose = 0). Summary infor-
mation on formoterol, salmeterol and tiotropium,
collected in the studies included in this pooled analy-
sis, was also added (complete model equations are
described in Additional file 1). The Bayesian analyses
were implemented with Markov chain Monte Carlo
methods using WinBUGS software version 1.4.3 [16].
For each analysis the posterior distribution of the
structural model parameters and key derived para-
meters were summarized as mean, median, standard
deviation, as well as 2.5th and 97.5th quantiles, which
provided 95% CIs for each parameter. Data are pre-
sented for six indacaterol doses corresponding to the
two doses at which indacaterol is approved in many
countries (150 and 300 μg), together with doses equal
to double the highest approved dose (i.e. 600 μg), half
the lowest approved dose (i.e. 75 μg), and two lower
doses (18.5 and 37.5 μg ) .T h er e s p o n s e st ot h ec o m -
parators are included for reference.
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For the patient-level analysis, a nonlinear mixed effects
(NLME) model was used [17], based on an Emax dose-
response model:
E0 + E0i +
Emax × exp(Emi) × doseij
ED50 + doseij
(2)
where i is an index for patient and j for study day (14
or 15), E0 i st h er e s p o n s et op l a c e b o ,a n dE 0i and Emi
are random effects to account for inter-patient variation
in response. NLME models are often used for the pur-
poses of pooling individual patient data as they allow
the differences between patients to be accounted for in
an unbiased manner as fixed effects (e.g. patient charac-
teristics such as age and disease status) and random
effects (e.g. the remaining random differences that can-
not be accounted for by patient characteristics).
T h eb a s em o d e li n c l u d e di n t e r-individual variability
(E0i and Emi) to account for within-patient correlation of
the observed responses, as well as covariate adjustments
(effect of baseline FEV1 on E0 and Emax, and effect of
reversibility following administration of a short-acting
b2-agonist on Emax). A transform-both-sides approach
was used, with the logarithm transformation applied to
both the response and the model. An additive residual
error term was specified after log transformation. The
primary goal was to derive an estimate of the dose
response for the improvement over placebo in trough
FEV1 based on individual measurements in each patient.
The patient-level analysis incorporated patient charac-
teristics, such as disease-relevant covariates, and enabled
evaluation of consistency between the two different
modelling approaches. Model building proceeded with a
forward entry procedure relying on the likelihood ratio
test. Tested covariates were: baseline FEV1 (average of
pre-treatment FEV1 values), COPD severity (moderate
or lower vs severe or worse, based on the classification
of severity of COPD defined in the GOLD 2007 guide-
lines [18]) use of inhaled corticosteroids, smoking status
(ex vs current smoker), gender, age (<65 years vs ≥ 65
years), study day, and study. The final model equation is
described in full in Additional file 1. NLME modelling
was carried out using SAS/STAT software (procedure
NLMIXED), version 9.2 of the SAS system for Unix.
The first order estimation method was specified.
Results
Study-level analysis
The data used in the study-level analysis of trough FEV1
are shown in figure 3. Each point represents a LSM con-
trast to placebo (expressed in mL) as determined for
each visit (from Week 2 to the end of the study) and
treatment arm of each study, for both indacaterol (left-
hand panel) and comparators (right-hand panel). Visual
inspection of the indacaterol data points indicated that
with increasing dose the response asymptotically
approached a maximum plateau. The majority of study
results for doses of 75 μg and above exceeded the
MCID of 120 mL (dotted line on the graph).
The outcome of the study-level analysis of the 24-h
trough values is also presented in figure 3, as the red
solid line, representing the mean dose response curve,
and two greyed areas representing 95% confidence limits
for the curve (darker area) and approximate 95% predic-
tion limits (lighter area) for the data points. The three
Table 1 Studies of indacaterol included in the study-level pooled analysis (all studies) and patient-level analysis
(B2335S and B2356)
Design Patients Indacaterol dose, μg Pbo For Sal Tio
18.75 37.5 75 150 300 600
Cross-over, 14-day 96 144
‡ 72 72
Parallel-group, 52-week 1732 437 428 432 435
Parallel-group 26-week 2059 130 420 418 123 425 123 420
Crossover, 14-day 68 66 66 65
Parallel-group, 12-week 416 211 205
Parallel-group, 12-week 347* 114 116 117
Parallel-group, 26-week 563 188 188 187
Parallel-group, 26-week 1002 333 335 334
Parallel-group, 12-week 323 163 160
Parallel-group, 12-week 318 159 159
Parallel-group, 12-week 552 92 91 94 92 91 92
7476 92 91 546 1358 1369 551 2249 558 563 420
All studies were placebo-controlled. Values are numbers of patients (the sum of totals across the columns for indacaterol dose and comparators is greater than
the total number of patients randomized due to the inclusion of cross-over studies). *Asian patients;
‡73 morning dosing vs 71 evening dosing. Pbo = placebo;
For = formoterol 12 μg bid; Sal = salmeterol 50 μg bid; Tio = tiotropium 18 μgq d
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FEV1 responses for each of the comparators included in
this analysis. The most striking feature of the plot is
that the response to indacaterol at the plateau exceeds
the response of all comparators. In other words, doses
of indacaterol 150 μg or greater provide greater average
trough bronchodilation than the comparators.
The mean estimate for the ED50 was 28 μg, with a 95%
CI ranging between 12 and 52 μg (Table 2); this is the
dose that is predicted to produce half the maximum
response than can be achieved by indacaterol. The mean
Emax estimate was 177 mL with a 95% CI ranging
between 152 and 206 mL; this is the predicted average
maximum response. Based on these parameter estimates,
the relative potency of the other tested doses can be cal-
culated: 37.5, 75, 150, 300 and 600 μgp r o v i d e d5 9 ,7 4 ,
85, 92 and 96% of the model-predicted maximal effect,
respectively (Table 2). This suggests that doses of 75 μg
or less are on the steep part of the dose response, 150 μg
is at the threshold of the plateau and 300 μga n dh i g h e r
are on the plateau.
A key advantage of a comprehensive quantitative char-
acterization of the dose response is that it allows gen-
eration of precise probabilistic statements about the
relative responses. Figure 4 presents (normalized) distri-
butions for the mean improvements vs placebo at each
dose level that underpin such calculations. Using these
distributions, it is possible to calculate, for example, that
the probability that the mean improvement vs placebo
in trough FEV1 for 37.5 μg exceeds the MCID is 7%
while the probability that 75 μg exceeds the MCID is
about 90% (the corresponding probability was approxi-
mately 99.9% for 150 μg). In other words, 75 μgi st h e
most likely lowest tested dose that exceeds the MCID.
Figure 5 presents the quantification of the dose
response, with the response to each indacaterol dose or
each comparator ranked by the predicted response. The
dots represent the point estimates and the grey lines are
the 95% CIs. In this presentation, it is evident that an
indacaterol dose of 37.5 μgi sl e s st h a nt h eM C I Da n d
that doses of 75 μg or greater exceed the MCID. How-
ever, indacaterol 75 μg overlaps the tiotropium response,
whereas indacaterol 150 μg or greater exceeds the tio-
tropium response. Indacaterol 300 μg is the lowest dose
that overlaps the maximum response; indacaterol 150 μg
occupies the middle ground between the MCID and the
maximum response, and has a response greater than
any of the comparators. This analysis suggests that
150 μg is the optimal indacaterol dose.
Since this analysis relied on study-level summaries
(LSM), it is possible to assess the predictive performance
of these data. This is important, as study-level summa-
ries are often used to support dose-selection decisions
Figure 3 Prediction of dose response for trough FEV1 at steady
state in the study-level analysis with comparators.
Table 2 Posterior summaries for parameters from the
model of trough FEV1 at steady state in the study-level
analysis
Mean SD Q2.5 Q50 (median) Q97.5
Model parameters
Emax (mL) 177 13 152 176 206
ED50 (μg) 28 10 12 26 52
Derived parameters
ED90 (μg) 110 41 46 105 207
Effect as percentage of maximum effect
18.75 μg 42 9 27 42 62
37.5 μg 59 9 42 59 76
75 μg 74 7 59 74 87
150 μg 85 5 74 85 93
300 μg 92 3 85 92 96
600 μg 96 2 92 96 98
Q2.5 and Q97.5 are the 2.5th and 97.5th quantiles, respectively, and
correspond to the 95% CI for each parameter. SD = standard deviation.
Figure 4 Posterior distributions of improvement over placebo
at steady-state trough FEV1 (study-level analysis).
Renard et al. Respiratory Research 2011, 12:54
http://respiratory-research.com/content/12/1/54
Page 5 of 9for bronchodilators. In figure 3, the light grey shaded
area provides the 95% prediction interval for the data,
i.e. data from 95% of study visits from trials similar to
those used in this programme are expected to fall within
this interval of ±60 mL. This is an expression of the dif-
ficulty in differentiating doses using conventional
approaches for typically sized studies.
Patient-level analysis
The patient-level analysis, although restricted to the two
dose-ranging studies, provided a characterization of dose
response that was similar to that obtained in the study-
level analysis. The final NLME model used for the patient-
level analysis produced a slightly steeper dose-response for
the typical COPD patient representative of the population
in the two studies. The estimated maximum effect (Emax)
and ED50 were respectively 185 mL (95% CI = 163, 210)
and 19 μg (95% CI = 10, 36). This translated into indaca-
terol 18.75 μg providing 49% of the maximum trough
FEV1 effect, compared with 66% for indacaterol 37.5 μg,
79% for indacaterol 75 μg, 89% for indacaterol 150 μg,
94% for indacaterol 300 μg and 97% for indacaterol 600 μg.
Unlike the study-level analysis, the patient-level analy-
sis enabled the exploration of patient characteristics that
may influence the shape of dose-response. In particular,
the covariate search leading to the final NLME model
revealed that baseline FEV1, which may be considered as
a marker of disease severity, was the key covariate. The
impact of baseline FEV1 o nt h ed o s er e s p o n s ei nt h e
absence of any model-based interpretation is shown in
figure 6. The figure shows the individual patient trough
FEV1 measurements split into quartiles depending on
the patients’ baseline FEV1 values. The LOESS curves in
each panel, again intended to highlight the main trends,
are also displayed in the right-hand plot, after subtrac-
tion of the placebo effect. This gives a visual impression
of how the trough FEV1 dose response changed with
baseline FEV1.A sb a s e l i n eF E V 1 increased, both the
steepness and the maximum of the dose response
increased. In particular, the lowest quartile, with a base-
line FEV1 of less than 1 L, had a much flatter dose
response.
The patient-level model quantifies this overall rela-
tionship precisely and demonstrates that both the maxi-
mum response (Emax) and the sensitivity (ED50)t oa
bronchodilator are strongly influenced by the baseline
FEV1. In other words, as disease severity increases (i.e.
baseline FEV1 decreases), patients require higher doses
to obtain an optimal response. This relationship can be
Figure 5 Ranking of efficacy by dose (study-level analysis).
Figure 6 Left: patient-level dose response data by baseline FEV1 category (quartiles) with LOESS curves through the data; Right:
zoom-in on smooth curves represented in a three-dimensional manner, after subtracting the placebo effect, to highlight dependency
of the response on dose and baseline FEV1 (note: the mid-value of the intervals is taken for each baseline FEV1 category in the right-
hand plot).
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highlights the dependency of the trough FEV1 response
on both dose and baseline FEV1 and shows that as base-
line FEV1 increases, the dose-response curve becomes
steeper and reaches a higher maximum level. This ana-
lysis suggests that the heterogeneity observed in a typi-
cal COPD population may require a more differentiated
approach to tailoring therapy to disease status.
To better understand the relationship between dose
and baseline FEV1 for patients with differing baseline
values, the relative improvement achievable across the
dose range was considered. Figure 8 presents the per-
centage improvement in trough FEV1 according to base-
line values across the dose range. As baseline FEV1
decreases (i.e., severity increases), there is a decrease in
the relative improvement across all doses. However, this
decrease is strongest for doses of 75 μg or lower. Doses
of 150 μg or higher provide sustained bronchodilation
that is largely independent of disease severity.
Finally, it is instructive to place the findings of this
analysis in the context of the GOLD classification of
COPD severity [19]. For this purpose, patients were
divided according to the GOLD classification of moder-
ate COPD or better and severe COPD or worse, and the
average dose responses for the respective groups were
predicted (figure 9). Patients with moderate COPD are
predicted to have a steeper dose response with a larger
maximum response, whereas patients with severe COPD
have a shallower dose response with a lower maximum
response. These findings suggest that, for the purpose of
effective treatment of COPD, a “one dose fits all”
approach may not be most appropriate.
Discussion
Conventional dose-ranging trials for bronchodilators,
such as those used to evaluate tiotropium, salmeterol
and formoterol [8,10-12,20], rely on hypothesis testing
and use of contrast statistics and do not provide a rigor-
ous basis for identification of the minimally effective,
optimal or maximum doses. This is due to the low sig-
nal-to-noise ratio inherent in the measurement of FEV1
and the poor precision of the conventional methodolo-
gies. Simply increasing trial size is not a viable option
because the patient numbers required to attain sufficient
precision to differentiate active treatments over the dose
range would be prohibitively large. To overcome this
methodological limitation, alternative approaches were
explored using the large indacaterol database to provide
a rigorous evaluation of the indacaterol dose response in
COPD.
The study-level analysis provided a precise characteri-
zation of the dose response using study level data. Data
from 11 studies, ranging from 2 to 52 weeks over a dose
Figure 8 Impact of baseline FEV1 and dose on the
improvement in trough FEV1 relative to baseline.
Figure 7 Three dimensional representation of predicted trough
FEV1 improvement at steady state for typical COPD patient as
a function of dose and baseline value.
Figure 9 Prediction of dose response for trough FEV1 at steady
state in typical patient with moderate or severe COPD
according to the predefined GOLD criteria.
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data from 7476 patients and with treatment arm sizes
ranging from 65 to 437 patients. Despite the large
within- and between-study variability, the analysis was
able to meet the requirements of a dose-ranging analy-
sis, namely to precisely differentiate doses over the effec-
tive range. Although not shown, a similar pattern was
seen in an analysis of peak FEV1 (observed peak or area
under the curve over 0-4 h post-dose).
Beyond the characterization of the indacaterol dose
response itself, the study-level analysis provides unique
insights into the precision of the conclusions that may
be drawn from typical trials that investigate the efficacy
of bronchodilators. Given the typical variability in FEV1,
it is not possible to precisely determine the metrics such
as the MED or differentiate active treatments using pair-
wise comparisons in typically sized trials. The implica-
tion is that the conventional approaches to dose-ranging
of bronchodilators cannot easily meet their quantitative
objectives. Only through pooling information in a model
based approach is it possible to attain the precision
necessary to draw robust quantitative conclusions on
treatment responses.
While the overall objective of the patient level analysis
was also to characterize the dose response, it had the
further aim of quantifying the impact of patient charac-
teristics on dose response and ultimately dose selection.
The patient level analysis dataset was restricted to the
two dose-ranging studies as these were most relevant to
the question at hand. Although restriction of the analysis
to 2-week data contrasts with the study-level pooled ana-
lysis (which pooled data between Week 2 and Month 6),
the similar outcomes from the two analyses reinforce the
overall conclusions while providing further insights into
the impact of patient characteristics on dose response.
The key finding of the patient level analysis was that
baseline FEV1, as a marker of disease severity, is the most
important patient characteristic that influences the dose
response. As disease progresses (baseline FEV1 decreases)
t h es h a p eo ft h ed o s er e s p o n s ec h a n g e s .H o w e v e r ,w i t h
doses of 150 μg or greater, the relative response becomes
more or less independent of baseline. In other words,
doses of 150 μg or greater are required to ensure that
patients can achieve optimal benefit. This finding is parti-
cularly pertinent to the 25% of the studied COPD popula-
tion with baseline FEV1 less than 1 L. To our knowledge,
this analysis is the first to demonstrate and quantify a rela-
tionship between COPD severity and dose response.
A number of measures are available for quantifying
dyspnoea (e.g. transition dyspnoea index [TDI], the Borg
scale and the visual analog scale). TDI is widely used to
assess dyspnoea [21] and was the only measure employed
consistently across all studies included in our analyses. It
measures change from baseline dyspnoea index over
time, and comprises three components (functional
impairment, magnitude of task and magnitude of effort),
each rated from 0 (severe dyspnoea) to 4 (no dyspnoea)
[22]. It has been reported that there is a correlation
between changes in FEV1 and patient-reported outcomes
such as TDI [23]. The higher differences from placebo in
FEV1 with indacaterol doses of 150 μg and higher seen in
our analyses would therefore be expected to result in
greater improvements in these patient-reported out-
comes. In support of this, indacaterol doses of 150 and
300 μg have been shown to result in significantly greater
improvements in TDI than placebo in patients with mod-
erate-to-severe COPD, with the 300 μgr e s u l t i n gi n
numerically (although not statistically) greater improve-
ments than indacaterol 150 μg [2]. This correlation
between FEV1 and TDI support the concept of identify-
ing the minimum indacaterol doses that provide near
maximum bronchodilation so as to optimize the clinical
benefit.
It is worth briefly commenting on the presented meth-
ods in the context of the original dose selection. Conven-
tional dose-ranging trials rely on hypothesis testing and
use contrast statistics to compare dose levels and deter-
mine the existence of a dose response. Using placebo cor-
rected means to characterize the dose response and
distinguish between doses is not robust if the CIs overlap;
for FEV1 this is the case even in very large trials. The key
difference between the approaches presented in this
manuscript and conventional methods is the use of an
explicit model, in this case the Emax model, to pool infor-
mation across dose levels. It is the pooling of information
that provides the greater precision compared to the con-
ventional method, which relies simply on each indepen-
dent point estimate. In terms of overall efficiency, the
patient level analysis of the dose response provides the
greatest level of insight for the least number of patients
studied. However, a key prerequisite for such an analysis is
that data on an adequate dose range is available. In the
current analysis, it was necessary to combine two studies
to achieve this goal. While this requirement for a wider
dose range and larger study population may be considered
a drawback of model based methods, it has been suggested
this is the price necessary to pay for adequate and robust
characterization of the dose response [7].
While the conventional approach originally selected the
150 and 300 μg doses, uncertainty remained about their
location on the dose response and, in particular, the effi-
cacy provided by these doses relative to the MCID. The
current analyses support the selection of 150 and 300 μg
as the lowest doses that ensure optimal response across
the spectrum of disease severity, while identifying 75 μga s
the MED. The direct clinical benefit of this analysis is that
it confirms the selection of doses of indacaterol that pro-
vide incremental benefit over other bronchodilators at
Renard et al. Respiratory Research 2011, 12:54
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Page 8 of 9levels that are at the threshold of the maximum trough
response.
In conclusion, thorough analysis of dose response is
critical to the successful evaluation of drug treatments
in COPD. Model-based approaches such as those
described here should allow more informed decisions to
be made regarding doses for further evaluation by com-
plementing the results from more classical dose-ranging
studies. These comprehensive analyses of the dose
response of indacaterol in COPD, showed that 75 μgi s
the MED of indacaterol and confirms that indacaterol
150 and 300 μg are expected to provide optimal bronch-
odilation, particularly in patients with severe disease.
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